COMMUNIQUÉS West-GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

03/03/2025 - 22:45

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a [...]

23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki

03/03/2025 - 22:35

SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a non-binding proposal [...]

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

03/03/2025 - 22:35

Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients [...]

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03/03/2025 - 22:30

MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

03/03/2025 - 22:30

PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified Cortrophin® Gel (repository [...]

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

03/03/2025 - 22:30

TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor [...]

Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

03/03/2025 - 22:30

Nyxoah to Participate in the Oppenheimer 35 th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – March 3, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ [...]

Nyxoah Participera à la 35ème Oppenheimer Annual Healthcare MedTech & Services Conference

03/03/2025 - 22:30

Nyxoah Participera à la 35 ème Oppenheimer Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgique – 3 mars 2025, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » [...]

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

03/03/2025 - 22:23

Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billion Fourth Quarter 2024 Net Loss of $31.3 million, decrease in Net Loss of 37% versus prior year Fourth Quarter 2024 [...]

Tenaya Therapeutics Announces Proposed Public Offering

03/03/2025 - 22:10

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]

Amwell makes inducement grant

03/03/2025 - 22:05

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leader in technology-enabled care, today announced that, on March 3, 2025, it made a grant of restricted stock units (“RSUs”) covering 220,844 shares [...]

Venus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

03/03/2025 - 22:05

TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2024 [...]

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

03/03/2025 - 22:05

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

03/03/2025 - 22:05

Received FDA approval for Eversense ® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to approximately 6,000 global [...]

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

03/03/2025 - 22:05

BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]

The Ensign Group Continues Growth in Arizona

03/03/2025 - 22:05

SAN JUAN CAPISTRANO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior [...]

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

03/03/2025 - 22:05

FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA (1) of $164.6 Million, a 309% YoY [...]

NeuroPace to Present at the Leerink Partners Global Healthcare Conference

03/03/2025 - 22:05

MOUNTAIN VIEW, Calif. , March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management [...]

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

03/03/2025 - 22:05

Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full study enrollment [...]